Big pharma has warned Australia to expand its poppy growing industry amid fears of a supply crunch, the FT reports.» Read More
Billionaire investor Warren Buffett revealed the names of two railroad stocks recently purchased by his holding company Berkshire Hathaway, according to documents filed with the U.S. Securities and Exchange Commission.
Warren Buffett, known for buying undervalued stocks, is boosting his bet on health care, a sector known more for growth than value.
Stocks moved broadly higher and the Dow logged triple-digit gains as investors were encouraged by large investments revealed by several billionaire investors. "We're in a bull market without any question," said Ned Riley, CEO of Riley Asset Management. "You can't deny this market because there is so much money being invested."
Another setback for Amgen anemia-drug franchise sent shares of the No. 1 biotechnology company spiraling down as much as 6.6% on Tuesday -- to a 2-1/2-year low -- as more analysts cut their ratings on the beaten-down stock.
Regulation approval in China recently hurt this company, but Cramer says there's reason to believe the business is on the MEND.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.
Stocks ended broadly higher after new economic data raised hopes of a Fed rate cut, and investors were quick to jump back into the market following recent declines. "I'm not surprised to see the market snap back," said Alec Young, market strategist at S&P Equity Research. "The market was kind of overbought -- it was an excellent opportunity for a shakeout."
Several investment banks slashed their ratings on Amgen shares following the disclosure that a U.S. advisory panel called for marketing restrictions on popular anemia drugs sold by Amgen and Johnson & Johnson.
Stocks will take their direction from economic data today after yesterday's drenching from negative April chain store sales took the Dow down 147 points and bit 1.7% off the Nasdaq and 1.4% off the S&P 500. European markets are lower, following overnight weakness in Asian markets.
Stocks sold off across the board, and the Dow fell almost 150 points, after mixed economic data prompted investors to book gains. "A day like today was inevitable," said Michael Cuggino of Permanent Portfolio Funds. "I would caution investors not to get overly concerned based on today's (economic) statistics."
Shares of Amgen and Johnson & Johnson traded lower after a U.S. advisory panel called for marketing restrictions on the companies' popular anemia drugs.
While I'm watching the webcast of the FDA Advisory Committee Meeting on the anemia drugs (Amgen, Johnson & Johnson), I wanted to hop on my TV versus print soapbox one more time.As I posted yesterday, I had asked a Dendreon spokeswoman for an interview with CEO Dr. Mitchell Gold in the wake of the FDA sending the company an "approvable letter" for its prostate cancer treatment Provenge.
Joseph Keating, chief investment officer at First American Asset Management, told CNBC’s “Squawk on the Street” that dividend stocks are a good bet in retirement.
In TV's worst spring in recent memory, an alarming number of Americans drifted away from television the past two months: More than 2.5 million fewer people were watching ABC, CBS, NBC and Fox than at the same time last year, statistics show.
Two studies and an editorial in the journal of the American Medical Association are raising even more questions about the safety of drug-coated stents and could further hurt already-declining sales.
Michael Krensavage, pharmaceutical analyst at Raymond James, told CNBC’s “Morning Call” that strong revenue and earnings growth will reward investors in the pharmaceutical sector.
U.S. Food and Drug Administration staffers on Tuesday expressed continued caution over the use of anemia drugs sold by Amgen and Johnson & Johnson , according to an agency document released on Tuesday.
Johnson & Johnson on Monday said it will meet a prior 2007 earnings forecast despite the failure of a highly-anticipated heart device in a key study.
Searching for nuggets of wisdom from the Oracle of Omaha.
Earnings blowouts and encouraging drug trials were some of the catalysts behind Thursday's most actively traded stocks.
Schering-Plough reported strong first-quarter results, surpassing consensus estimates by a wide margin due to robust sales of cholesterol drugs and allergy treatments.